Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002140 | A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients | PHASE3 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 24 | United States |
| Name | Type | Description |
|---|---|---|
| Ethambutol hydrochloride | DRUG | - |
| Clarithromycin | DRUG | - |
| Azithromycin | DRUG | - |
Inclusion Criteria Patients must have: * HIV seropositivity. * Disseminated MAC. * No MAC therapy between time of last positive blood culture draw and study entry (single-agent prophylaxis allowed). * Life expectancy of at least 2 months. * Consent of parent or guardian if below legal age of conse...